Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Orchestra Biomed Holdings Inc OBIO

Technology Scientific & Technical Instruments
Orchestra BioMed Holdings, Inc. is a biomedical innovation company. Its lead product candidate is BackBeat Cardiac Neuromodulation Therapy (BackBeat CNT) for the treatment of hypertension (HTN), the leading risk factor for death worldwide. It is also developing the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for the treatment of atherosclerotic artery disease, the leading cause of... see more

Recent & Breaking News (NDAQ:OBIO)

Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting

GlobeNewswire December 9, 2024

Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference

GlobeNewswire November 26, 2024

Orchestra BioMed Reports Third Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire November 12, 2024

Orchestra BioMed to Participate in Jefferies London Healthcare Conference

GlobeNewswire November 7, 2024

Orchestra BioMed Reports Second Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire August 12, 2024

Orchestra BioMed Announces Appointment of Cardiovascular Device Industry Expert John Mack to Board of Directors

GlobeNewswire July 30, 2024

Orchestra BioMed Announces Further Details on In-Person R&D Day in New York Featuring Key Opinion Leaders to Discuss AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

GlobeNewswire June 4, 2024

Orchestra BioMed to Participate in Jefferies Global Healthcare Conference

GlobeNewswire May 22, 2024

Orchestra BioMed Reports First Quarter 2024 Financial Results and Provides a Business Update

GlobeNewswire May 13, 2024

Orchestra BioMed Announces AVIM Therapy Global Intellectual Property Estate Reaches 110 Issued Patents

GlobeNewswire April 30, 2024

Orchestra BioMed to Host In-Person R&D Day in New York on AVIM Therapy Program in Hypertensive Pacemaker Patients on June 11, 2024

GlobeNewswire April 30, 2024

Orchestra BioMed Reports Full Year 2023 Financial Results and Provides Fourth Quarter Business Update

GlobeNewswire March 27, 2024

Orchestra BioMed Announces Appointment of Medical Device Industry Expert David Pacitti to Board of Directors

GlobeNewswire March 26, 2024

Orchestra BioMed Demonstrates Strength of Cardiovascular Pipeline with Virtue® SAB and AVIM Therapy Presentations at CRT 2024 Annual Meeting

GlobeNewswire March 13, 2024

Orchestra BioMed to Participate in Upcoming Investor Conferences

GlobeNewswire March 7, 2024

Orchestra BioMed Announces Presentation of Results from Clinical Study Demonstrating Favorable Hemodynamic Effects of AVIM Therapy In Hypertensive Pacemaker Patients

GlobeNewswire March 6, 2024

Orchestra BioMed Presents New Data Showing Sustained Clinically Meaningful Reduction in 24-Hour Ambulatory Systolic Blood Pressure in Hypertensive Pacemaker Patients Treated with AVIM Therapy for Over 3 Years

GlobeNewswire February 26, 2024

Orchestra BioMed Announces Initiation of BACKBEAT Pivotal Study of AVIM Therapy in Hypertensive Pacemaker Patients

GlobeNewswire January 8, 2024

Orchestra BioMed Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 13, 2023

Orchestra BioMed to Present at Upcoming Investor Conferences

GlobeNewswire November 9, 2023